Mateos María-Victoria, Ludwig Heinz, Bazarbachi Ali, Beksac Meral, Bladé Joan, Boccadoro Mario, Cavo Michele, Delforge Michel, Dimopoulos Meletios A, Facon Thierry, Geraldes Catarina, Goldschmidt Hartmut, Hájek Roman, Hansson Markus, Jamroziak Krzysztof, Leiba Merav, Masszi Tamás, Mendeleeva Larisa, O'Dwyer Michael, Plesner Torben, San-Miguel Jesús F, Straka Christian, van de Donk Niels W C J, Yong Kwee, Zver Samo, Moreau Philippe, Sonneveld Pieter
Complejo Asistencial Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (CAUSA/IBSAL), Salamanca, Spain.
Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria.
Hemasphere. 2018 Dec 27;3(1):e163. doi: 10.1097/HS9.0000000000000163. eCollection 2019 Feb.
The introduction of new agents and management strategies over the past decade has resulted in a major step change in treatment outcomes with deepening responses and increased survival for patients with multiple myeloma. In daily clinical practice, healthcare professionals are now faced with challenges including, optimal treatment sequencing and changing treatment goals. In light of this, a group of experts met to discuss diagnostic and treatment guidelines, examine current clinical practice, and consider how new clinical trial data may be integrated into the management of multiple myeloma in the future.
在过去十年中,新药物和管理策略的引入使多发性骨髓瘤患者的治疗结果取得了重大飞跃,缓解程度加深,生存率提高。在日常临床实践中,医疗保健专业人员现在面临着诸多挑战,包括优化治疗顺序和改变治疗目标。有鉴于此,一组专家齐聚一堂,讨论诊断和治疗指南,审视当前的临床实践,并思考如何在未来将新的临床试验数据纳入多发性骨髓瘤的管理中。